- Oscar Health’s growth strategy depends on ACA marketplace expansion, with plans to enter more than 150 additional metropolitan areas by 2027, although subsidy uncertainty and rising medical costs remain significant risks.
- Oscar reported 2.96 mn members and $4.88 bn in second-quarter revenue. It subsequently raised its 2026 operating earnings guidance to $600-800 mn.
- Analyst valuations remain divided, with an average price target of $35.40 contrasting sharply with an investor-backed discounted cash flow estimate of $583.34, which depends on aggressive growth assumptions.
Healthcare insurtech Oscar Health (OSCR) has emerged as one of the stronger-performing U.S. health insurance stocks in 2026, with shares gaining more than 130% as investors respond to accelerating Affordable Care Act (ACA) marketplace enrollment, improving underwriting results and higher earnings expectations.
As of October 9, 2026, the latest completed trading session was October 8, when Oscar Health shares closed at $33.10, up $0.19, or 0.58%. The stock advanced approximately 10.7% over the preceding five trading sessions and 130.3% from its December 31, 2025 closing price of $14.37.
The rally lifted Oscar’s market capitalization to approximately $10.21 bn, with shares approaching the upper end of their 52-week trading range of $10.69 to $34.48.
The company’s financial performance provides support for the recent gains. Oscar reported stronger membership growth, higher revenue and a substantial improvement in profitability during the first half of 2026. Its expansion plans could extend that momentum, although dependence on ACA policy, rising medical costs and increasingly demanding valuations remain important considerations.
Oscar’s growth strategy centers on expanding its presence in the individual health insurance market through technology-driven products, personalized services and relationships with healthcare providers.
Enhanced ACA premium subsidies historically improved coverage affordability and supported marketplace enrollment. Their expiration at the end of 2025 has introduced additional uncertainty for insurers focused on the individual market.
Oscar’s ability to retain members, adjust premium pricing and manage medical expenses will determine how successfully it operates under the changed subsidy environment.
Second-quarter 2026 revenue reached $4.88 bn, compared with $2.86 bn in the corresponding period of 2025. The increase reflected higher membership and premium rate adjustments, partially offset by changes in risk adjustment transfers.
- Oscar reported net income attributable to shareholders of $361.8 mn, equivalent to diluted earnings per share of $1.10. A year earlier, it recorded a net loss of $228.4 mn, or $0.89 per share.
- Operating earnings reached $388.6 mn, reversing a $230.5 mn operating loss in the second quarter of 2025.
- Underwriting performance improved substantially. Oscar’s medical loss ratio declined to 79.2% from 91.1% a year earlier, a reduction of 11.9 percentage points.
The improvement reflected disciplined pricing and $164 mn in favorable prior-period reserve development, although the unusually high prior-year ratio also reflected risk adjustment developments.
Administrative efficiency improved as the business expanded. Oscar’s selling, general and administrative expense ratio fell to 14.2% from 18.7%, reflecting expense controls, greater fixed-cost leverage and changes in the relationship between risk adjustment and premium revenue.
Membership growth supported these results. Oscar served approximately 2.96 mn effectuated members as of June 30, 2026, compared with 2.03 mn a year earlier.
The increase illustrates the company’s ability to expand its insurance portfolio while reducing operating expenses relative to revenue.
At its September 16 investor presentation, the company raised its 2026 operating earnings guidance to between $600 mn and $800 mn, compared with its previous forecast of $500 mn–$700 mn.
Management also lowered its projected full-year medical loss ratio to 81.0%–82.0%, an improvement of 50 basis points from the earlier guidance range.
Oscar maintained its revenue forecast of $18.7 bn–$19 bn and its selling, general and administrative expense ratio guidance of 15.6%–16.1%.
The revisions indicate that management expects better underwriting profitability without increasing its full-year revenue expectations.
Geographic expansion remains a central component of Oscar’s longer-term strategy. The company plans to enter more than 150 additional metropolitan statistical areas by 2027, expanding access to potential customers and increasing its presence in the ACA marketplace.
During its September investor presentation, management also outlined plans to expand into another 400–600 counties by 2029. Oscar expects its addressable market to increase from approximately 9.6 mn to 16 mn individuals, while targeting a national ACA market share of more than 18%.
The company is developing additional insurance products and distribution capabilities to support that expansion. Its CHOICE membership has approximately doubled year over year, while more than 250 off-exchange products are being introduced for 2027.
These initiatives could diversify distribution channels and allow Oscar to address changing consumer demand for individually selected health insurance coverage.
The strategy also increases execution requirements. Geographic expansion exposes insurers to differences in provider costs, competitive conditions and regional claims experience. Entering additional markets without accurate pricing could weaken underwriting margins even if enrollment continues to rise.
Changes in federal subsidies can affect the affordability of health insurance and influence the number and characteristics of individuals maintaining coverage.
Reduced affordability could increase member attrition, particularly among healthier consumers who may be more willing to forgo insurance. A deterioration in the membership risk profile could increase medical loss ratios and require additional premium adjustments.
Rising healthcare utilization presents a separate challenge. Even with disciplined pricing, unexpected increases in claims frequency or treatment costs can erode underwriting profitability.
These risks are shared across the government-sponsored health insurance market, although their effect differs according to each company’s business mix.
Oscar’s greater concentration in ACA marketplace products creates a more direct relationship between its financial performance and changes in individual-market conditions.
Its valuation reflects substantial expectations for continued growth and improved profitability. As of the latest available market data, Oscar Health traded at approximately 4.97 times book value, above the industry average of 2.64 reported in a recent Zacks assessment.
Oscar’s second-quarter results demonstrate that enrollment growth and better cost management can translate into stronger earnings. Its updated 2026 guidance also indicates confidence in profitability for the remainder of the year.
Following a 130.3% year-to-date share-price increase, the relationship between growth and valuation has become particularly important. Oscar’s ability to sustain underwriting margins, maintain efficient operations and generate earnings from its expanding membership base will determine whether its recent financial improvement supports the expectations now reflected in its stock price.
